Could a common bone drug help control HIV?

NCT ID NCT07216794

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study tests whether alendronate, a drug used for bone loss, can reduce the hidden HIV reservoir in people already on HIV medication. About 30 participants will receive either alendronate or a placebo, and researchers will measure changes in HIV DNA in the blood. The goal is to see if this approach can help control the virus long-term, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chapel Hill (Site ID: 3201)

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ohio State University (Site ID: 2301)

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California, San Francisco HIV/AIDS (Site ID: 801)

    San Francisco, California, 94110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Colorado Hospital (Site ID: 6101)

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh (Site ID: 1001)

    Pittsburgh, Pennsylvania, 15213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.